20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Conformis Inc (NASDAQ:CFMS) announced results of a published retrospective study of procedures using Conformis' patient-specific iTotal CR (cruciate-retaining) knee replacement implant.
- Data showed that implant survivorship was 98.5% with 8 revisions (representing 1.5% of the 540 implants reviewed) at a mean follow-up of 2.8 years.
- 89% of the patients reported being either satisfied or highly satisfied.
- The researchers reviewed patient records and conducted patient report outcome surveys of 540 knees in 433 patients who underwent personalized total knee arthroplasty.
- Related Link: Investors React To Conformis' Annual Sales Guidance Update.
- Price Action: CFMS stock is up 1.55% at $1.31 during the premarket session on the last check Thursday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!